- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00942435
A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
June 14, 2010 updated by: Astellas Pharma Inc
A Randomized, Open Label Parallel Group Mechanical Prophylaxis Controlled Comparison Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
The purpose of the study is to evaluate the efficacy and safety of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients undergoing major abdominal surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
156
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chubu, Japan
-
Chugoku, Japan
-
Hokkaido, Japan
-
Kansai, Japan
-
Kantou, Japan
-
Shikoku, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients after a major abdominal surgery
- Written informed consent obtained
Exclusion Criteria:
- Subject has history of symptomatic deep vein thrombosis and/or pulmonary embolism
- Subject has a hemorrhagic disorder and/or coagulation disorder
- Subject has had clinically important bleeding occurred within 90 days prior to the screening visit
- Subject has an active bacterial endocarditis
- Subject has uncontrolled severe or moderate hypertension, retinopathy, myocardial infarction or stroke
- Subject is receiving anticoagulants/antiplatelet agents
- Subject has a thrombocytopenia
- Body weight less than 40 kg at the screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: YM150 group
|
oral
|
Active Comparator: mechanical prophylaxis group
|
The investigator will determine the method of mechanical prophylaxis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite assessment of venous thromboembolism events and all causes of death
Time Frame: Until day 12
|
Until day 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of venous thromboembolism
Time Frame: Until day 28
|
Until day 28
|
Incidence of bleeding events
Time Frame: Until day 28
|
Until day 28
|
All cause mortality
Time Frame: Until day 28
|
Until day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
July 16, 2009
First Submitted That Met QC Criteria
July 16, 2009
First Posted (Estimate)
July 20, 2009
Study Record Updates
Last Update Posted (Estimate)
June 16, 2010
Last Update Submitted That Met QC Criteria
June 14, 2010
Last Verified
June 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 150-CL-042
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on YM150
-
Astellas Pharma IncCompletedAtrial FibrillationGermany, Korea, Republic of, Australia, Poland, United Kingdom, Japan, South Africa, Russian Federation, Austria, Estonia, Thailand, Bulgaria, France, Spain, Ukraine, India, Israel, Hungary, Slovakia, Malaysia, Philippines, Czech... and more
-
Astellas Pharma IncCompletedArthroplasty, Replacement, KneeUnited States, Canada
-
Astellas Pharma IncCompletedAtrial FibrillationTaiwan, Japan, Korea, Republic of, New Zealand, Singapore, South Africa, Thailand, Australia, Hong Kong, Malaysia
-
Astellas Pharma IncCompletedThromboembolismSingapore, Indonesia, Japan, Korea, Republic of, Malaysia, Philippines, Taiwan, Thailand
-
Astellas Pharma Europe B.V.CompletedVenous Thromboembolism | Arthroplasty, Replacement, HipDenmark, Spain, United States, Austria, Colombia, Russian Federation, India, Italy, United Kingdom, Germany, Hungary, Estonia, Romania, South Africa, Israel, Poland, Sweden, Canada, Australia, Lithuania, Ukraine, Latvia, Finland, Brazil, Slovak... and more
-
Astellas Pharma IncCompletedVenous ThromboembolismJapan, Taiwan, Thailand
-
Astellas Pharma IncCompletedVenous ThromboembolismJapan, Korea, Republic of, Taiwan, Thailand
-
Astellas Pharma IncCompletedVenous ThromboembolismJapan
-
Astellas Pharma IncCompletedHealthy Volunteer | Pharmacokinetics of YM150Japan
-
Astellas Pharma IncCompletedVenous ThromboembolismJapan